| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$26 |
Preliminary Financial Report - 30 June 2025
|
29 Aug 2025 8:36AM |
$0.022 |
$0.043 |
risen by
95.45%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Pathkey.AI Ltd changed its name from Opyl Limited.
- The company reported a net loss after income tax of AUD 1,447,743 for the year ending 30 June 2025.
- Revenue from contracts with customers was significantly lower at AUD 27,783 compared to the previous year.
- Government grants and incentives added AUD 292,869 to other income.
- Net cash used in operating activities was AUD 1,284,285.
- Net cash from financing activities amounted to AUD 1,351,163.
- The issued capital increased to AUD 23,640,010.
- The company invested AUD 329,400 in the Digital Bitcoin ETF.
- Pathkey.AI Ltd remained in a net liability position at year-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$26 |
Preliminary Financial Report - 30 June 2025
|
29 Aug 2025 8:36AM |
$0.022 |
$0.043 |
risen by
95.45%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues decreased by 93.0% to $27,783.
- Loss after tax reduced by 53.8% to $1,447,743.
- No dividends declared or paid during the financial period.
- Net tangible assets per ordinary security stood at -0.11 cents.
- Employee benefits and consultancy costs decreased.
- Significant loss from ordinary activities reflects operational challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jatcorp Limited (JAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$16 |
Preliminary Final and Full Year Statutory Accounts
|
29 Aug 2025 8:36AM |
$0.320 |
$0.145 |
fallen by
54.69%
|
|
JAT - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant decline in revenue and earnings for FY25.
- Revenue from continuing operations fell by 34% to $34.8 million.
- Group consolidated revenue decreased by 54%.
- Net loss after tax was $6.9 million, down from a profit of $1.6 million in 2024.
- Impairment losses and inventory write-downs impacted financial results.
- Adjusted EBITDA turned negative, indicating operational challenges.
- Market expansion efforts included increased online distribution in China.
- Cash balance at the end of the year was $2.7 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jatcorp Limited (JAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$16 |
Preliminary Final and Full Year Statutory Accounts
|
29 Aug 2025 8:36AM |
$0.320 |
$0.145 |
fallen by
54.69%
|
|
JAT - Price-sensitive ASX Announcement
Full Release
Key Points
- Jatcorp Limited reported a loss after tax of $2,465,944 for the year ended 30 June 2025, compared to a profit of $2,219,619 the previous year.
- Revenue from continuing operations decreased by 34% to $34,840,126.
- The company did not declare or pay any dividends during the financial year.
- The Group is economically dependent on sales to the People's Republic of China, which constituted 35% of total revenue.
- There was a significant impairment loss of $2,573,115 recognized due to the suspension of sales of Neurio® products in China.
- Jatcorp Ltd's net tangible assets per ordinary security fell from 9.766 cents to 4.672 cents.
- The company consolidated its share capital on a 30-for-one basis during the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Volt Group Limited (VPR) ORDINARY FULLY PAID |
Utilities |
$25 |
Appendix 4D and Half Yearly Financial Report
|
29 Aug 2025 8:36AM |
$0.115 |
$0.155 |
risen by
34.78%
|
|
VPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues decreased by 24% to $2.15 million.
- Net loss of $271,854 compared to previous year's profit.
- EcoQuip revenue grew by 38%.
- Wescone impacted by order receipt timing.
- Investments in EcoQuip fleet and R&D activities.
- ATEN Concept Study shows carbon reduction benefits.
- 1 for 100 share consolidation on 2 June 2025.
- On-market share buy-back announced.
- Changes in company directorship.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Volt Group Limited (VPR) ORDINARY FULLY PAID |
Utilities |
$25 |
Appendix 4D and Half Yearly Financial Report
|
29 Aug 2025 8:36AM |
$0.115 |
$0.155 |
risen by
34.78%
|
|
VPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 24% compared to the previous year.
- EcoQuip business segment observed a 38% growth in revenue.
- Significant investment in EcoQuip Mobile Solar Light Tower fleet and R&D.
- Completed a 1 for 100 share consolidation on 2 June 2025.
- Net operating cash inflow of $267,565.
- Reported loss of $271,854 for the half-year.
- Continued focus on expanding technological and equipment capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$49 |
Vection Reports FY25 Results
|
29 Aug 2025 8:35AM |
$0.050 |
$0.021 |
fallen by
58%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro-forma revenue of $42.0 million for FY25.
- Reported revenue increased by 8.7% to $37.5 million.
- First positive underlying EBITDA of $2.8 million.
- Successful integration of The Digital Box acquisition.
- Significant growth driven by Defence sector contracts.
- Expansion in education, healthcare, and industrial sectors.
- Focus on sustainable profitability and global expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$49 |
Vection Reports FY25 Results
|
29 Aug 2025 8:35AM |
$0.050 |
$0.021 |
fallen by
58%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported revenue increased by 8.7% to AUD 37.5 million.
- First positive EBITDA recorded at AUD 2.8 million.
- Pro-forma revenue of AUD 42.0 million including TDB.
- Significant growth driven by the Defence sector.
- Acquisition of The Digital Box (Algho AI) bolstered AI capabilities.
- Positive operating cash flow demonstrating operational leverage.
- Investments in AI and Spatial Computing are central to strategy.
- Vection's presence expanded in sectors like healthcare and retail.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:33AM |
$0.003 |
$0.045 |
risen by
1,700%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- Visionflex Group Limited (ASX: VFX) presented its FY25 results on 29 August 2025.
- The company focuses on empowering health practitioners globally with advanced technology for virtual care.
- Visionflex integrates its proprietary software with various third-party medical devices for clinical consultations.
- FY25 saw operating cashflow turn positive at $0.3 million in Q4.
- The company targets growth in aged care, home care, Indigenous health, and resources sectors.
- Visionflex transitioned to a SaaS model, achieving 49% annual recurring revenue (ARR) growth to $1.9 million.
- The company introduced a new software solution for the In-Home Care sector.
- Visionflex expanded its customer base across multiple industry verticals and government-funded customers.
- The balance sheet improved with material reductions in debt and enhanced liquidity.
- Positive outlook for FY26 focusing on SaaS revenue and leveraging strategic partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:33AM |
$0.003 |
$0.045 |
risen by
1,700%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- Visionflex transitioned to a SaaS model, increasing ARR by 49% to $1.9 million.
- Gross profit margin improved to 78%.
- Staff costs increased by 39% due to strategic investments.
- Finance costs were reduced by 64%, with further reductions expected.
- Cash balance of $1.9 million supports future growth.
- Secured government-funded contracts and partnerships in key sectors.
- Launched new solutions for the in-home care sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Audited Full Year Results
|
29 Aug 2025 8:33AM |
$0.003 |
$0.045 |
risen by
1,700%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $4.7 million, down 33% from previous year.
- Annual Recurring Revenue (ARR) increased by 49% to $1.9 million.
- Gross profit margin improved to 78%.
- Underlying EBITDA loss of $2.5 million, reflecting investments in growth.
- Reduced legacy debt from $6.8 million to $2.4 million.
- Key contracts signed with Amplar Health, BHP, Bupa, and others.
- Launched VisionHome for in-home care market expansion.
- Focus on building a sustainable, profitable organization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Audited Full Year Results
|
29 Aug 2025 8:33AM |
$0.003 |
$0.045 |
risen by
1,700%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- 49% increase in Annual Recurring Revenue (ARR) to $1.9 million.
- FY25 revenue was $4.7 million, down 33% due to previous large hardware contract.
- Recurring software and support revenue grew by 101% to $1.4 million.
- Gross profit margin increased to 78% from recurring software revenue.
- Underlying EBITDA loss of $2.5 million due to lower revenue and strategic investments.
- Legacy debt reduced from $6.8 million to $2.4 million.
- Ended FY25 with $1.9 million in cash.
- Key contracts with Amplar Health, BUPA, and the Royal Flying Doctor Service.
- Focus on market expansion and customer-led innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$337 |
Change in substantial holding
|
29 Aug 2025 8:33AM |
$1.260 |
$0.970 |
fallen by
23.02%
|
|
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$218 |
Change of Director's Interest Notice
|
29 Aug 2025 8:33AM |
$0.675 |
$0.730 |
risen by
8.15%
|
|
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$49 |
Preliminary Final Report
|
29 Aug 2025 8:33AM |
$0.050 |
$0.021 |
fallen by
58%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased to $36,003,000.
- Loss after income tax was $7,407,000.
- Significant expenses included asset impairments and share-based payments.
- Underlying EBITDA improved to $2,818,000.
- Acquisition of The Digital Box S.p.A. during the period.
- Focus on core operations with INTEGRATEDXR® solutions and services.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$49 |
Preliminary Final Report
|
29 Aug 2025 8:33AM |
$0.050 |
$0.021 |
fallen by
58%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Vection Technologies Ltd reported a total revenue of $37.502 million for 2025, with sales from the EMEA and APAC regions.
- The company's EBITDA for 2025 was $1.2 million, with depreciation and amortisation expenses amounting to $5.5 million.
- Impairment of assets for 2025 was recorded at $575,000.
- The company incurred a finance cost of $1.269 million in 2025.
- There was a loss before income tax benefit of $7.542 million for the year 2025.
- Segment assets for the year 2025 stood at $89.233 million, with intersegment eliminations reducing the total to $72.255 million.
- Total liabilities were $80.445 million with intersegment eliminations bringing it down to $60.578 million.
- Revenue from INTEGRATEDXR® solutions and services was consistent between 2024 and 2025.
- The company’s trade receivables for 2025 were $21.997 million with an allowance for expected credit losses of $1.006 million.
- Intangible assets, including goodwill, intellectual property, and software development costs, were noted with impairments.
- Bank loans constituted the majority of borrowings, amounting to $19.303 million in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Virgin Australia Holdings Limited (VGN) ORDINARY FULLY PAID |
Industrials |
$2,078 |
FY25 Appendix 4E and Preliminary Final Report
|
29 Aug 2025 8:32AM |
$3.490 |
$2.650 |
fallen by
24.07%
|
|
VGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Virgin Australia Group's underlying EBIT for FY25 is $664.4 million, up 27.9%.
- Statutory net profit after tax decreased by 12.3% to $478.5 million.
- Underlying revenue and income grew 8.5% to $5,809.7 million.
- Execution of Value Carrier strategy resulted in operational improvements.
- Velocity Loyalty program saw a 12% increase in active members.
- Investments in property and equipment totaled $603.7 million for FY25.
- Total assets for the group are $4,872.1 million with net liabilities of $814.6 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$8 |
Preliminary Final Report
|
29 Aug 2025 8:32AM |
$0.036 |
$0.013 |
fallen by
63.89%
|
|
NOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax for the year was $6.1 million.
- Total equity saw a deficiency of $879,000.
- Net cash used in operating activities was $11.3 million.
- Significant issuance of shares occurred.
- Sale of IBOA Group Holdings Pty Ltd resulted in a gain.
- Focus on reducing liabilities and optimizing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$8 |
Preliminary Final Report
|
29 Aug 2025 8:32AM |
$0.036 |
$0.013 |
fallen by
63.89%
|
|
NOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Novatti Group Limited reported a 24.1% increase in revenue to $50,482,000 for the year ended 30 June 2025.
- The company recorded a decreased net loss of $6,643,000, down from $20,603,000 in the previous year.
- There were no dividends paid, recommended, or declared during the financial year.
- The underlying EBITDA improved significantly, reflecting a loss of $3,059,000 compared to a restated loss of $11,382,000 in the prior year.
- The net asset position of the Group shifted from net assets of $241,000 to a net deficiency of $879,000 as of 30 June 2025.
- Cash and cash equivalents at the end of the year were $2,376,000.
- The Group underwent changes in equity, with issued capital increasing to $97,993,000 due to share issues and conversions.
- The financial report includes a plan to dispose of Emersion, a wholly-owned subsidiary, indicating ongoing restructuring activities.
- Novatti Group experienced a 73% reduction in EBITDA loss, driven by increased revenue and effective cost management.
- The financial year ended with continued efforts in restructuring and operational adjustments to enhance financial stability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Investment Management Ltd (CIW) ORDINARY FULLY PAID |
Financials |
$25 |
Update - Notification of buy-back - CIW
|
29 Aug 2025 8:32AM |
$0.390 |
$0.300 |
fallen by
23.08%
|
|
| Xamble Group Limited (XGL) CHESS DEPOSITARY INTERESTS 1:1 |
Communication Services |
$5 |
Rights Issue Commitment and Dispatch of Offer Documents
|
29 Aug 2025 8:32AM |
$0.024 |
$0.010 |
fallen by
58.33%
|
|
| Tesoro Gold Ltd (TSO) ORDINARY FULLY PAID |
Materials |
$172 |
Ternera Metallurgical Testing Delivers High Recoveries
|
29 Aug 2025 8:31AM |
$0.040 |
$0.960 |
risen by
2,300%
|
|
TSO - Price-sensitive ASX Announcement
Full Release
Key Points
- Gold recoveries exceed 95% using CIP processing.
- Low reagent consumption with less than 0.2 kg/t cyanide used.
- Utilized brine wastewater from Aguascap desalination plant.
- Consistent performance across different ore grades.
- Supports future process plant design and pre-feasibility studies.
- Master composite sample testing confirmed positive results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tesoro Gold Ltd (TSO) ORDINARY FULLY PAID |
Materials |
$172 |
Ternera Metallurgical Testing Delivers High Recoveries
|
29 Aug 2025 8:31AM |
$0.040 |
$0.960 |
risen by
2,300%
|
|
TSO - Price-sensitive ASX Announcement
Full Release
Key Points
- Average gold recovery of 95% from Ternera composite samples at a 125 µm grind size
- Gravity recoverable gold consistent across all grade ranges at 41%
- Low cyanide consumption at less than 0.2 kg/t
- Utilizes bittern wastewater from Aguascap desalination plant
- Comminution testwork returned an average Bond Work Index of 20.9 kWh/t
- Supports process plant design and pre-feasibility study inputs
- Zeff Reeves comments on the milestone advancement for Ternera Gold Deposit
- Robustness and low-cost of current Ternera flowsheet confirmed
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,602 |
MSB Annual Financial Results and Operational Update
|
29 Aug 2025 8:31AM |
$2.420 |
$2.010 |
fallen by
16.94%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- First FDA product approval and launch of Ryoncil®.
- Revenue from cell therapy products rose to US$17.2 million, with a 191% increase.
- Net operating cash spend was US$50.0 million.
- Cash on hand was US$162 million as of June 30, 2025.
- Mesoblast added to S&P/ASX 200 Index and Nasdaq Biotechnology Index.
- Ryoncil® is the only FDA-approved MSC therapy for pediatric SR-aGvHD.
- Potential for FDA accelerated approval of Revascor® for heart failure.
- Rexlemestrocel-L in Phase 3 trials for chronic low back pain.
- Expansion of Ryoncil® into new indications, including adults with SR-aGvHD.
- Establishment of MyMesoblast™ for patient access and support.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,602 |
MSB Annual Financial Results and Operational Update
|
29 Aug 2025 8:31AM |
$2.420 |
$2.010 |
fallen by
16.94%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approval and commercial launch of Ryoncil®.
- Revenue growth to US$17.2 million, a 191% increase.
- Net loss of US$102.1 million due to commercialization expenses.
- Focus on expanding Ryoncil® for adult applications.
- Strong IP portfolio and financial backing.
- Commitment to innovative developments in cellular medicines.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
